Green JR - Search Results

1

Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF. Reid IR, et al. Among authors: green jr. Bone. 2020 Aug;137:115390. doi: 10.1016/j.bone.2020.115390. Epub 2020 Apr 27. Bone. 2020. PMID: 32353565

2

A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.

Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB. Gasser JA, et al. Among authors: green jr. Bone. 2006 Oct;39(4):787-95. doi: 10.1016/j.bone.2006.04.035. Epub 2006 Jul 17. Bone. 2006. PMID: 16844441

3

Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat.

Müller K, Wiesenberg I, Jaeggi K, Green JR. Müller K, et al. Among authors: green jr. Arzneimittelforschung. 1998 Jan;48(1):81-6. Arzneimittelforschung. 1998. PMID: 9522039

4

Anticancer properties of zoledronic acid.

Green J, Lipton A. Green J, et al. Cancer Invest. 2010 Nov;28(9):944-57. doi: 10.3109/07357907.2010.512598. Cancer Invest. 2010. PMID: 20879838 Review.

5

Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.

Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Gasser JA, et al. Among authors: green jr. J Bone Miner Res. 2008 Apr;23(4):544-51. doi: 10.1359/jbmr.071207. J Bone Miner Res. 2008. PMID: 18072878 Free article.

6

Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment.

Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WS. Pataki A, et al. Among authors: green jr. Anat Rec. 1997 Dec;249(4):458-68. doi: 10.1002/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N. Anat Rec. 1997. PMID: 9415453 Free article.

7

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.

Missbach M, Jeschke M, Feyen J, Müller K, Glatt M, Green J, Susa M. Missbach M, et al. Bone. 1999 May;24(5):437-49. doi: 10.1016/s8756-3282(99)00020-4. Bone. 1999. PMID: 10321903

8

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.

Green JR, Müller K, Jaeggi KA. Green JR, et al. J Bone Miner Res. 1994 May;9(5):745-51. doi: 10.1002/jbmr.5650090521. J Bone Miner Res. 1994. PMID: 8053405 Free article.

9

The molecular basis of bisphosphonate activity: a preclinical perspective.

Green J, Clézardin P. Green J, et al. Semin Oncol. 2010 Jun;37 Suppl 1:S3-11. doi: 10.1053/j.seminoncol.2010.06.003. Semin Oncol. 2010. PMID: 20682369 Review.

10

Preclinical pharmacology of zoledronic acid.

Green JR. Green JR. Semin Oncol. 2002 Dec;29(6 Suppl 21):3-11. doi: 10.1053/sonc.2002.37421. Semin Oncol. 2002. PMID: 12584689 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

946 results

Search Page